Klinik und Poliklinik für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie
Refine
Has Fulltext
- yes (134) (remove)
Is part of the Bibliography
- yes (134)
Year of publication
Document Type
- Journal article (75)
- Doctoral Thesis (58)
- Other (1)
Keywords
- ADHD (16)
- ADHS (12)
- children (11)
- Aufmerksamkeitsdefizit-Syndrom (6)
- adolescents (6)
- methylphenidate (6)
- Anorexia nervosa (5)
- Methylphenidat (5)
- adolescence (5)
- therapeutic drug monitoring (5)
Institute
- Klinik und Poliklinik für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie (134)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (26)
- Institut für Psychologie (11)
- Graduate School of Life Sciences (8)
- Neurologische Klinik und Poliklinik (5)
- Institut für Klinische Epidemiologie und Biometrie (4)
- Institut für diagnostische und interventionelle Neuroradiologie (ehem. Abteilung für Neuroradiologie) (3)
- Medizinische Klinik und Poliklinik I (3)
- Institut für Pharmakologie und Toxikologie (2)
- Institut für Sonderpädagogik (2)
Sonstige beteiligte Institutionen
- Deutsches Zentrum für Präventionsforschung Psychische Gesundheit (DZPP) (1)
- Integriertes Forschungs und Behandlungszentrum Adipositaserkrankungen (1)
- Klinik für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie des Leopoldina Krankenhaus Schweinfurt (1)
- Max-Planck-Institut für Kognitions- und Neurowissenschaften (1)
- Technische Universität Dresden (1)
Biological Substrates of Waiting Impulsivity in Children and Adolescents with and without ADHD
(2023)
Focus of the present work were the questions whether and how the concept of waiting impulsivity (WI), defined as the ability to regulate a response in anticipation of reward and measured by the 4-choice serial reaction time task (4-CSRTT), may contribute to our understanding of Attention-Deficit/Hyperactivity Disorder (ADHD) and its neurobiological underpinnings.
To address this topic, two studies were conducted: in a first study, the relationship be-tween 4-CSRTT behavioral measures, neural correlates and ADHD symptom domains, i.e. inattention (IA) and hyperactivity/impulsivity (H/I) was explored in a pooled sample of 90 children and adolescents with (n=44) and without (n=46) ADHD diagnosis. As ex-pected, IA was associated with dorsolateral prefrontal brain regions linked with executive functions and attentional control, which was evident on the structural and the functional level. Higher levels of both IA and H/I covaried with decreased activity in the right ven-trolateral prefrontal cortex (PFC), a central structure for response inhibition. Moderation analyses revealed that H/I-related decreased activation in this region did not map linearly on difficulties on the behavioral level: brain activation was a significant predictor of task accuracy only, when H/I symptoms were low/absent but not for clinically relevant ADHD symptoms. Further, H/I was implicated in dysfunctional top-down control of reward eval-uation. Both symptom domains correlated positively with hippocampus (HC) activity in anticipation of reward. In addition, for high H/I symptoms, greater activation in the HC was found to correlate with higher motivation on the behavioral level, indicating that rein-forcement-learning and/or contingency awareness may contribute to altered reward pro-cessing in ADHD patients.
In a second study, the possible serotonergic modulation of WI and the ADHD-WI relation-ship was addressed in a sub-sample comprising 86 children and adolescents of study I. The effects of a functional variant in the gene coding for the rate-limiting enzyme in the synthesis of brain serotonin on behavior and structure or function of the WI-network was investigated. Moderation analyses revealed that on the behavioral level, a negative corre-lation between accuracy and IA was found only in GG-homozygotes, whereas no signifi-cant relationship emerged for carriers of the T-allele. This is in line with previous reports of differential effects of serotonergic modulation on attentional performance depending on the presence of ADHD symptoms. A trend-wise interaction effect of genotype and IA for regional volume of the right middle frontal gyrus was interpreted as a hint towards an involvement of the PFC in this relationship, although a more complex mechanism includ-ing developmental effects can be assumed. In addition, interaction effects of genotype and IA were found for brain activation in the amygdala (AMY) und HC during perfor-mance of the 4-CSRTT, while another interaction was found for H/I symptoms and geno-type for right AMY volume. These findings indicate a serotonergic modulation of coding of the emotional value of reward during performance of the 4-CSRTT that varies de-pending on the extent of psychopathology-associated traits.
Taken together, it was shown that the 4-CSRTT taps distinct domains of impulsivity with relevance to ADHD symptomatology: (proactive) response inhibition difficulties in relation with anticipation of reward. Furthermore, the two symptom domains, IA and H/I, contrib-ute differently to WI, which emphasizes the need to distinguish both in the research of ADHD. The results of study II emphasized the relevance of serotonergic transmission especially for attentional control and emotional processing. Although the present findings need replication and further refinement in more homogenous age groups, the use of the 4-CSRTT with a dimensional approach is a very promising strategy, which will hopefully extend our understanding of impulsivity-related mental disorders in the future.
Durch die vorliegende Arbeit konnte störungsübergreifend ein Zusammenhang zwischen dem Tag der Motorik-Testung und dem IQ einerseits und den Testbefunden zur Motorik andererseits gezeigt werden. Es gelang nicht, den vermuteten negativen Einfluss von psychosozialen Faktoren auf motorische Fähigkeiten zu demonstrieren.
Bezüglich der ADHS-Medikation konnte aufgrund des Studiendesigns als Querschnittstudie keine klare Aussage getroffen werden, ob ein positiver Einfluss auf motorische Fähigkeiten vorliegt. Bei den Patient-/innen mit Hyperkinetischer Störung des Sozialverhaltens (F90.1) fanden sich zwar bei bestehender ADHS-Medikation signifikant bessere Testbefunde der Balance, es konnte jedoch nicht geklärt werden, warum der positive Effekt der ADHS-Medikation nur auf diese Störungsgruppe und den Balance-Untertest der M-ABC II begrenzt war.
Im Gruppenvergleich konnten signifikant bessere motorische Fähigkeiten der Patient-/innen mit internalisierender Störung als jener mit externalisierender Störung festgestellt werden. Damit kongruent kam die Diagnose einer UEMF (F82) in der Gruppe der externalisierenden Störungen häufiger vor. Da ein Großteil der Patient-/innen der externalisierenden Störungsgruppe an Defiziten der Aufmerksamkeit, Impulskontrolle und der Motivation litt, ist davon auszugehen, dass diese Symptome zu schwerwiegenden Beeinträchtigungen der motorischen Fähigkeiten und damit auch zu weiteren Problemen im Alltag oder bei der Schullaufbahn führen. Innerhalb der Gruppe der externalisierenden Störungen konnte hinsichtlich der motorischen Fähigkeiten kein Unterschied zwischen Patient-/innen mit Hyperkinetischen Störungen (F90.-) und solchen mit Störung des Sozialverhaltens (F91) gefunden werden. Ein solcher Unterschied hätte einen Hinweis geben können, ob eher Defizite der Aufmerksamkeit und Impulskontrolle oder ein Motivationsdefizit mit motorischen Einschränkungen verbunden sind. Hierbei ist anzumerken, dass die Gruppengrößen für einen validen Vergleich dieser Störungsgruppen nicht ausreichend waren.
Der Vergleich motorischer Fähigkeiten sowie der Häufigkeit einer UEMF (F82) zwischen Patient-/innen mit umschriebener Entwicklungsstörung des Sprechens und der Sprache (F80) einerseits und Patient-/innen mit umschriebener Entwicklungsstörung der schulischen Fertigkeiten (F81) andererseits bestätigte die Vermutung, dass bei Patient-/innen der Störungsgruppe F80 schlechtere motorische Fähigkeiten und signifikant mehr motorische Defizite vorlagen. Ein Teil dieses Unterschieds lässt sich jedoch durch den signifikant niedrigeren IQ der Störungsgruppe F80 erklären. Es muss darüber hinaus berücksichtigt werden, dass bei den umschriebenen Entwicklungsstörungen F80 und F81 eine häufige Komorbidität mit externalisierenden Störungen bestand, sodass motorische Defizite auch durch ein ursächliches Defizit der Aufmerksamkeit und Impulskontrolle erklärt werden könnten.
In vorgegangenen Studien wurde bei erwachsenen Patienten mit Angststörungen eine verstärkte Furchtgeneralisierung, eine eingeschränkte Fähigkeit zur Reizdiskrimination sowie eine veränderte Aufmerksamkeitsverteilung nachgewiesen. In einer gesunden Studienpopulation konnte bei Kindern eine stärkere Furchtgeneralisierung nachgewiesen werden als bei Erwachsenen. Ihre Generalisierungsgradienten gleichen denen von Erwachsenen mit Angststörung. Möglicherweise haben gestörte Lernprozesse in der Kindheit somit langfristige Effekte auf die Entwicklung von Angststörungen. Obwohl die Vorgänge des Furchtlernens im Kindesalter entscheidend für das Verständnis von Angststörungen sind, gibt es kaum Studien in dieser Altersgruppe. Die vorliegende Studie untersucht die Zusammenhänge von Furchtgeneralisierung und Aufmerksamkeitsprozessen in einer klinischen Population mit internalisierender Störung im Kindes- und Jugendalter.
Hierzu durchliefen Kinder und Jugendliche mit internalisierender Störung (n= 49) sowie gesunde Kontrollen (n=48) im Alter von 9 bis 17 Jahre ein Furcht-generalisierungsparadigma mit Diskriminationstraining sowie einen modifizierten Dotprobe mit integriertem Eyetracking. Die Ängstlichkeit wurde mittels verschiedener Angstfragebögen gemessen. Im Generalisierungsparadigma wurden zwei weibliche Gesichter mit neutralem Gesichtsausdruck als Stimuli verwendet, die entweder mit (CS+) oder ohne (CS-) einem 95dB lauten Schrei sowie einem angsterfüllten Gesichtsausdruck gezeigt wurden. Zur Messung der Furchtreaktion wurden subjektive Ratings für Arousal, Valenz und Kontingenz erfasst, zudem wurde die Hautleitfähigkeit gemessen. Zur Auswertung des Dotprobes wurden die Reaktionszeiten und die Initialsakkade erfasst. Die statistische Analyse des Furchtgeneralisierungsparadigmas sowie des Dotprobe-Paradigmas wurde mittels Multivarianzanalysen mit Messwiederholung durchgeführt, gefolgt von t-Tests zur weiterführenden Analyse. Desweiteren wurden die Aufmerksamkeitsreaktionen von nicht-ängstlichen und ängstlichen Teilnehmern in Kategorien eingeteilt und mittels Chi-Quadrat Analysen verglichen. Zur Analyse des Zusammenhangs zwischen Furchtgeneralisierung und Aufmerksamkeitsprozessen erfolgte eine Regressionsanalyse mit einem GS Mittelwert als abhängiger Variable und der Ängstlichkeit und den Aufmerk-samkeitsprozessen als Prädiktoren.
Die Ergebnisse bestätigten eine solide Furchtkonditionierung anhand des „Screaming Lady“-Paradigmas in einer klinischen Population, dies war erkennbar an höheren Ratings für den aversiven Stimulus im Vergleich zum sicheren Stimulus in beiden Gruppen. Grundsätzlich höhere Furchtratings sowie höhere Ratings der Generalisierungsstimuli im Vergleich zum sicheren Stimulus wiesen auf eine stärkere Generalisierung in der Untergruppe mit höherem Angst-Trait innerhalb der internalisierenden Probandengruppe hin. Die Analyse der Dotprobe Daten ergab schnellere Reaktionszeiten sowie häufigere Initialsakkaden gegenüber furchteinflößenden Stimuli bei Patienten mit internalisierender Störung. Des Weiteren zeigten sehr ängstliche Probanden häufiger einen Attentional bias im Chi Quadrat Test als nicht-ängstliche Probanden. Dies wies daraufhin, dass sowohl bei Patienten mit internalisierender Störung als auch bei sehr ängstlichen Probanden ein Attentional bias gegenüber furchtrelevanten Stimuli vorliegt. Vor allem bei Kindern mit internalisierender Störung sagten die Ängstlichkeit und veränderte Aufmerksamkeitsprozesse die Ausprägung der Furchtgeneralisierung voraus. Somit kann ein Zusammenhang von veränderten Aufmerksamkeitsprozessen und Furchtgeneralisierung vermutet werden.
(1) Background: Evidence has accumulated that patients with anorexia nervosa (AN) are at higher risk for vitamin D deficiency than healthy controls. In epidemiologic studies, low 25(OH) vitamin D (25(OH)D) levels were associated with depression. This study analyzed the relationship between 25(OH)D serum levels in adolescent patients and AN and depressive symptoms over the course of treatment. (2) Methods: 25(OH)D levels and depressive symptoms were analyzed in 93 adolescent (in-)patients with AN from the Anorexia Nervosa Day patient versus Inpatient (ANDI) multicenter trial at clinic admission, discharge, and 1 year follow up. Mixed regression models were used to analyze the relationship between 25(OH)D levels and depressive symptoms assessed by the Beck Depression Inventory (BDI-II). (3) Results: Although mean 25(OH)D levels constantly remained in recommended ranges (≥50 nmol/L) during AN treatment, levels decreased from (in)patient admission to 1 year follow up. Levels of 25(OH)D were neither cross-sectionally, prospectively, nor longitudinally associated with the BDI-II score. (4) Conclusions: This study did not confirm that 25(OH)D levels are associated with depressive symptoms in patients with AN. However, increasing risks of vitamin D deficiency over the course of AN treatment indicate that clinicians should monitor 25(OH)D levels.
Members of the family of metabotropic glutamate receptors are involved in the pathomechanism of several disorders of the nervous system. Besides the well-investigated function of dysfunctional glutamate receptor signaling in neurodegenerative diseases, neurodevelopmental disorders (NDD), like autism spectrum disorders (ASD) and attention-deficit and hyperactivity disorder (ADHD) might also be partly caused by disturbed glutamate signaling during development. However, the underlying mechanism of the type III metabotropic glutamate receptor 8 (mGluR8 or GRM8) involvement in neurodevelopment and disease mechanism is largely unknown. Here we show that the expression pattern of the two orthologs of human GRM8, grm8a and grm8b, have evolved partially distinct expression patterns in the brain of zebrafish (Danio rerio), especially at adult stages, suggesting sub-functionalization of these two genes during evolution. Using double in situ hybridization staining in the developing brain we demonstrate that grm8a is expressed in a subset of gad1a-positive cells, pointing towards glutamatergic modulation of GABAergic signaling. Building on this result we generated loss-of-function models of both genes using CRISPR/Cas9. Both mutant lines are viable and display no obvious gross morphological phenotypes making them suitable for further analysis. Initial behavioral characterization revealed distinct phenotypes in larvae. Whereas grm8a mutant animals display reduced swimming velocity, grm8b mutant animals show increased thigmotaxis behavior, suggesting an anxiety-like phenotype. We anticipate that our two novel metabotropic glutamate receptor 8 zebrafish models may contribute to a deeper understanding of its function in normal development and its role in the pathomechanism of disorders of the central nervous system.
Mental disorders at the beginning of adolescence: Prevalence estimates in a sample aged 11-14 years
(2022)
Objectives
This study aims to provide a deeper insight into mental disorders in early adolescence. We report prevalence rates (mental health problems, depressive symptoms, eating disorders, NSSI, STBs) to be used in future studies and clinical ventures. We also expected to find gender differences, with girls being be more affected than boys are.
Study design
877 adolescents (M = 12.43, SD = 0.65) from seven German high schools completed a series of questionnaires assessing their mental health (SDQ, PHQ-9, SEED, DSHI-9, Paykel Suicide Scale, FAS III).
Methods
We calculated cut-off-based prevalence estimates for mental health issues for the whole sample and compared estimates between genders.
Results
12.5% of the sample reported general mental health problems. The estimated prevalence of depressive symptoms lay at of 11.5%. Additionally, 12.1% and 1.3% of the participants displayed relevant symptoms of anorexia or bulimia nervosa, respectively. A total of 10.8% reported engaging in non-suicidal self-injury (NSSI) at least once in their lifetime, of whom 5.6% reported repetitive NSSI. 30.1% of the participants described suicidal thoughts, 9.9% suicide plans, and 3.5% at least one suicide attempt. Girls were generally more affected than boys, except for bulimia nervosa, suicidal behavior, and partly NSSI.
Conclusion
Our findings corroborate the established relevance of early adolescence for the development of mental health problems and suggest that a substantial proportion of young adolescents suffer from such problems early on. Considering the ongoing COVID-19 pandemic and reported negative mental health consequences, the current findings underline the importance of preventive interventions to avoid the manifestation of mental disorders during adolescence.
Background
Chronic stress is detrimental to health, and children and young people have had to cope with significantly more stress since the start of the COVID-19 pandemic. In particular, stress at school and in relation to learning is a major problem in this age group. Studies in Germany have indicated that the pandemic has led to a reduced quality of life (QoL) and an increased risk for psychiatric disorders in children and adolescents. Schools are an ideal setting for interventions against stress, which is one of the strongest predictors for the development of psychosocial problems. The present study seeks to address stress by means of a short prevention training programme in schools, including emotion regulation, mindfulness, and self-compassion. In addition to information material for self-study, students should have the opportunity to actively deal with the topic of stress and develop coping strategies within a short space of time. In contrast to very long stress reduction programmes that often last several weeks, the programme is delivered in just 90 min.
Methods
The effectiveness of the short and economical prevention programme LessStress will be examined in a cluster-randomised controlled trial (RCT) encompassing 1894 students. At several measurement time points, students from two groups (intervention and control) will be asked about their subjectively perceived stress levels, among other aspects. Due to the clustered nature of the data, mainly multilevel analyses will be performed.
Discussion
In Germany, there are no nationwide universal prevention programmes for students against stress in schools, and this gap has become more evident since the outbreak of the pandemic. Universal stress prevention in schools may be a starting point to promote resilience. By dealing with stress in a healthy way, mental health can be strengthened and maintained. Moreover, to reach at-risk students at an early stage, we advocate for a stronger networking between child psychiatry and schools.
Background
The efficacy of parent-child training (PCT) regarding child symptoms may be reduced if the mother has attention-deficit/hyperactivity disorder (ADHD). The AIMAC study (ADHD in Mothers and Children) aimed to compensate for the deteriorating effect of parental psychopathology by treating the mother (Step 1) before the beginning of PCT (Step 2). This secondary analysis was particularly concerned with the additional effect of the Step 2 PCT on child symptoms after the Step 1 treatment.
Methods
The analysis included 143 mothers and children (aged 6–12 years) both diagnosed with ADHD. The study design was a two-stage, two-arm parallel group trial (Step 1 treatment group [TG]: intensive treatment of the mother including psychotherapy and pharmacotherapy; Step 1 control group [CG]: supportive counseling only for mother; Step 2 TG and CG: PCT). Single- and multi-group analyses with piecewise linear latent growth curve models were applied to test for the effects of group and phase. Child symptoms (e.g., ADHD symptoms, disruptive behavior) were rated by three informants (blinded clinician, mother, teacher).
Results
Children in the TG showed a stronger improvement of their disruptive behavior as rated by mothers than those in the CG during Step 1 (Step 1: TG vs. CG). In the CG, according to reports of the blinded clinician and the mother, the reduction of children’s disruptive behavior was stronger during Step 2 than during Step 1 (CG: Step 1 vs. Step 2). In the TG, improvement of child outcome did not differ across treatment steps (TG: Step 1 vs. Step 2).
Conclusions
Intensive treatment of the mother including pharmacotherapy and psychotherapy may have small positive effects on the child’s disruptive behavior. PCT may be a valid treatment option for children with ADHD regarding disruptive behavior, even if mothers are not intensively treated beforehand.
Trial registration
ISRCTN registry ISRCTN73911400. Registered 29 March 2007.
Background
In individuals suffering from a rare disease the diagnostic process and the confirmation of a final diagnosis often extends over many years. Factors contributing to delayed diagnosis include health care professionals' limited knowledge of rare diseases and frequent (co-)occurrence of mental disorders that may complicate and delay the diagnostic process. The ZSE-DUO study aims to assess the benefits of a combination of a physician focusing on somatic aspects with a mental health expert working side by side as a tandem in the diagnostic process.
Study design
This multi-center, prospective controlled study has a two-phase cohort design.
Methods
Two cohorts of 682 patients each are sequentially recruited from 11 university-based German Centers for Rare Diseases (CRD): the standard care cohort (control, somatic expertise only) and the innovative care cohort (experimental, combined somatic and mental health expertise). Individuals aged 12 years and older presenting with symptoms and signs which are not explained by current diagnoses will be included. Data will be collected prior to the first visit to the CRD’s outpatient clinic (T0), at the first visit (T1) and 12 months thereafter (T2).
Outcomes
Primary outcome is the percentage of patients with one or more confirmed diagnoses covering the symptomatic spectrum presented. Sample size is calculated to detect a 10 percent increase from 30% in standard care to 40% in the innovative dual expert cohort. Secondary outcomes are (a) time to diagnosis/diagnoses explaining the symptomatology; (b) proportion of patients successfully referred from CRD to standard care; (c) costs of diagnosis including incremental cost effectiveness ratios; (d) predictive value of screening instruments administered at T0 to identify patients with mental disorders; (e) patients’ quality of life and evaluation of care; and f) physicians’ satisfaction with the innovative care approach.
Conclusions
This is the first multi-center study to investigate the effects of a mental health specialist working in tandem with a somatic expert physician in CRDs. If this innovative approach proves successful, it will be made available on a larger scale nationally and promoted internationally. In the best case, ZSE-DUO can significantly shorten the time to diagnosis for a suspected rare disease.
There is no approved drug for fibromyalgia syndrome (FMS) in Europe. In the German S3 guideline, amitriptyline, duloxetine, and pregabalin are recommended for temporary use. The aim of this study was to cross-sectionally investigate the current practice of medication in FMS patients in Germany. We systematically interviewed 156 patients with FMS, while they were participating in a larger study. The patients had been stratified into subgroups with and without a decrease in intraepidermal nerve fiber density. The drugs most commonly used to treat FMS pain were nonsteroidal anti-inflammatory drugs (NSAIDs) (41.0% of all patients), metamizole (22.4%), and amitriptyline (12.8%). The most frequent analgesic treatment regimen was “on demand” (53.9%), during pain attacks, while 35.1% of the drugs were administered daily and the remaining in other regimens. Median pain relief as self-rated by the patients on a numerical rating scale (0–10) was 2 points for NSAIDS, 2 for metamizole, and 1 for amitriptyline. Drugs that were discontinued due to lack of efficacy rather than side effects were acetaminophen, flupirtine, and selective serotonin reuptake inhibitors. Reduction in pain severity was best achieved by NSAIDs and metamizole. Our hypothesis that a decrease in intraepidermal nerve fiber density might represent a neuropathic subtype of FMS, which would be associated with better effectiveness of drugs targeting neuropathic pain, could not be confirmed in this cohort. Many FMS patients take “on-demand” medication that is not in line with current guidelines. More randomized clinical trials are needed to assess drug effects in FMS subgroups.